ATOSSA THERAPEUTICS I

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

07 May 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

29 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

15 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

11 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 Apr 2024 11:59:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

05 Apr 2024 09:58:53 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 Apr 2024 11:38:29 By NetDania Notify

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

01 Apr 2024 12:27:21 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

28 Mar 2024 10:08:00 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

26 Mar 2024 09:45:03 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

25 Mar 2024 10:40:51 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

20 Mar 2024 09:45:01 By NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

19 Mar 2024 10:49:14 By NetDania Notify

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

19 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

18 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

12 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

22 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire